*	OR T4 T3
R1	Has_value Arg1:T2 Arg2:T4	
R2	Has_index Arg1:T7 Arg2:T8	
R3	Has_temporal Arg1:T6 Arg2:T7	
R4	Has_qualifier Arg1:T9 Arg2:T10	
R5	Has_value Arg1:T11 Arg2:T12	
R6	AND Arg1:T9 Arg2:T11	
R7	Has_value Arg1:T13 Arg2:T14	
R8	Has_temporal Arg1:T13 Arg2:T15	
R9	Has_multiplier Arg1:T16 Arg2:T18	
R10	Has_negation Arg1:T16 Arg2:T17	
R11	Has_temporal Arg1:T16 Arg2:T19	
R12	Has_temporal Arg1:T20 Arg2:T21	
R13	Has_index Arg1:T21 Arg2:T22	
T1	Person 0 5	Adult
T2	Measurement 51 54	MDS
T3	Value 31 50	intermediate-1 risk
T4	Value 24 27;46 50	low risk
T6	Drug 83 111	hematopoietic growth factors
T7	Temporal 112 146	within 3 months prior to screening
T8	Reference_point 137 146	screening
T9	Condition 160 166	anemia
T10	Qualifier 148 159	Symptomatic
T11	Measurement 168 178	hemoglobin
T12	Value 179 187	<10 g/dL
T13	Measurement 220 240	Serum erythropoietin
T14	Value 241 267	<500 milliunits/milliliter
T15	Temporal 276 333	within 14 days prior to the first dose of study treatment
T16	Procedure 346 372	red blood cell transfusion
T17	Negation 343 345	no
T18	Multiplier 389 397	<4 units
T19	Temporal 398 431	within 8 weeks prior to screening
T20	Condition 444 450	stable
T21	Temporal 451 501	for at least 1 month prior to entry into the study
T22	Reference_point 481 501	entry into the study
T23	Pregnancy_considerations 503 707	For female participants of childbearing potential and male participants with partners of childbearing potential, agreement (by participants and/or partner) to use highly effective form(s) of contraception
